IASLC TTLC 2022 | Concurrent checkpoint inhibition with chemoradiotherapy in NSCLC

Patients with stage III non-small cell lung cancer (NSCLC) typically receive either chemotherapy or radiotherapy and then durvalumab if they progress as per data from the Phase III PACIFIC trial (NCT02125461). Nathan Pennell, MD, PhD, Cleveland Clinic, Cleveland, OH, talks on treating with immunotherapy with chemotherapy or radiotherapy in stage III NSCLC. In stage IV NSCLC, immunotherapy with chemoradiotherapy has proven to be effective but is not the standard of care in stage III NSCLC. Prof. Pennell emphasizes the need for patients in earlier stages of NSCLC to receive immunotherapy and chemoradiotherapy together to improve outcomes. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).